Open AccessInflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
Author(s) -
Held Claes,
White Harvey D.,
Stewart Ralph A. H.,
Budaj Andrzej,
Can Christopher P.,
Hochman Judith S.,
Koenig Wolfgang,
Siegbahn Agneta,
Steg Philippe Gabriel,
Soffer Joseph,
Weaver W. Douglas,
Östlund Ollie,
Wallentin Lars
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.005077
Subject(s) - medicine , interquartile range , hazard ratio , cardiology , myocardial infarction , dyslipidemia , population , c reactive protein , heart failure , quartile , confidence interval , disease , inflammation , environmental health
Evaluation of cardiovascular prognosis in patients with stable coronary heart disease is based on clinical characteristics and biomarkers indicating dysglycemia, dyslipidemia, renal dysfunction, and possibly cardiac dysfunction. Inflammation plays a key role in atherosclerosis, but the association between inflammatory biomarkers and clinical outcomes is less studied in this population.